Trial Profile
A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2015
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- 16 May 2015 Status changed from recruiting to discontinued as reported by EU Clinical Trials Register record.
- 09 Jul 2014 New trial record